Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential therapy for new highly infectious Strain B.1.1.7 of Coronavirus
Hørsholm, Denmark (26 January 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the “British variant”), at the Pathogen and Microbiome Institute at Northern Arizona University (NAU).
The virus variant was labelled “Variant of Concern 202012/01” by Public Health England (PHE), an agency of the UK Department of Health & Social Care, in a publication on 21 December 2020, after it was found to have spread rapidly within the UK, and the PHE assessed that this variant has a substantially increased transmissibility compared with other Coronavirus variants. This variant has also been identified in the U.S. in several states.
Based on the previous positive pre-clinical test results with stenoparib as a treatment of SARS-CoV-2, announced on 26 August 2020, Allarity Therapeutics will now test the similar ability of stenoparib to block the infection and replication of SARS-CoV-2 lineage B.1.1.7. The tests will be conducted at the Pathogen and Microbiome Institute, a leading U.S. infectious disease test center.
The previous series of pre-clinical studies, for SARS-CoV-2, with results first announced on 26 August 2020, have since been published in the peer-review journal mBio (mbio.asm.org) on 19 January 2021. The data show that stenoparib inhibits SARS-CoV-2 as a single agent. In addition, stenoparib in combination with remdesivir was active in inhibiting coronavirus in vitro. The concentration of stenoparib required for virus inhibition was lower in the combination study than in the single agent study. The two drugs target the virus through unique but different mechanisms of action.
Stenoparib (formerly 2X-121, E7449) is a small molecule, targeted inhibitor of Poly ADP-Ribose Polymerase (PARP), a key DNA damage repair enzyme active in tumors, which was originally developed by the pharmaceutical company Eisai. Besides investigating whether stenoparib has therapeutic potential as a possible treatment of SARS-CoV-2 and the British variant (lineage B.1.1.7), Allarity Therapeutics is also currently evaluating stenoparib for the treatment of advanced ovarian cancer in a Phase 2 clinical trial at the Dana-Farber Cancer Institute (Boston, MA U.S.A.) using a DRP® companion diagnostic to guide patient enrollment and improve therapeutic outcome.
“We are excited to be one of the first few companies to be working on a possible treatment for the new variant by further testing, pre-clinically, the therapeutic potential of stenoparib against the British variant of Coronavirus, given the positive results of our prior pre-clinical tests of the drug as an anti-viral treatment for SARS-Cov-2,” said Steve R. Carchedi, CEO of Allarity Therapeutics. “We intend to work with FDA and NIH, as well as other funding sources, to advance stenoparib as soon as possible into clinical trials for the treatment of COVID-19 and/or the British variant. Exploring our novel drug as a promising new treatment for COVID-19 underscores our company commitment to develop new therapies for the improvement of patient care, and we are pleased to do whatever we can to provide a meaningful impact on solutions to this global pandemic.”
Paul Keim, NAU Regents’ Professor and PMI executive director, said “The emergence of SARS-CoV-2 variants is a challenge to our current approaches to COVID-19. They necessitate the validation of our diagnostics, vaccines, and therapeutics against a panel of these new and dangerous strains. B.1.1.7, in particular, has to be included in order for us to choose the right approaches and drugs for this disease.”
Allarity Therapeutics has applied for stenoparib to become a part of what is popularly known as Operation Warp Speed, a partnership among components of the US government, including the Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), as mentioned in a company announcement published on 14 December 2020. Specifically, Allarity Therapeutics has submitted a phase 2/3 protocol through the BARDA portal, and if this proposal is successful it may lead to a fully or partially government funded development process of stenoparib as a treatment of SARS-Cov-2.
About Allarity Therapeutics
Allarity Therapeutics (Nasdaq First North Growth Market Stockholm: ALLR.ST) develops drugs for personalized treatment of cancer guided by its proprietary drug response predictor technology, the DRP® platform. The company has a mature portfolio of six drug candidates, including compounds in the pre-registration stage. The product portfolio includes: stenoparib (2X-121), a PARP inhibitor in Phase 2 for ovarian cancer; dovitinib, a pan-TKI advancing towards a new drug approval (NDA) for renal cell carcinoma; IXEMPRA® (Ixabepilone), a microtubulin inhibitor approved in the U.S. for the treatment of breast cancer; LiPlaCis®, a liposomal formulation of cisplatin in Phase 2 trials for breast and prostate cancer; 2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer; and Irofulven, a DNA damaging agent in Phase 2 for prostate cancer.
About Northern Arizona University
Northern Arizona University is a higher-research institution providing exceptional educational opportunities in Arizona and beyond. NAU delivers a student-centered experience to its nearly 30,000 students in Flagstaff, statewide and online through rigorous academic programs in a supportive, inclusive and diverse environment. Dedicated, world-renowned faculty help ensure students achieve academic excellence, experience personal growth, have meaningful research opportunities and are positioned for personal and professional success.
About the Drug Response Predictor – DRP® Companion Diagnostic
Allarity uses its drug specific DRP® to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, the response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and prior clinical trial outcomes. DRP® is based on messenger RNA from the patient’s biopsies. DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in nearly 40 clinical studies that were examined, including an ongoing, prospective Phase 2 trial. The DRP® platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs.
Follow us on social media:
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of Allarity’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning Allarity’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. Allarity undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Carrotize PR & Communications
+45 6062 9390
Svensk Kapitalmarknadsgranskning AB, Email: email@example.com. Tel: +46 11 32 30 732
This information is information that Allarity A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on 26 January 2021.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Better Collective – Share buyback program completed5.3.2021 19:30:00 CET | Press release
Regulatory Release 4/2021 On March 4, 2021 Better Collective A/S initiated a share buyback program for up to EUR 100,000, to be executed during the period from March 4, 2021 to March 31, 2021. The following transactions have been executed under the program on March 5, 2021 Date Number of sharesAverage weighted purchase price (SEK per share)Amount (SEK)05/03/20213,532197.2223696,598.16Accumulated under the program following above purchase:3,532197.2223696,598.16 Better Collective A/S holds 3,773 treasury shares corresponding to 0,01 % of the outstanding share capital of the company. The share buyback program is hereby completed. Contacts Investor Relations: Christina Bastius Thomsen +45 2363 8844 e-mail: firstname.lastname@example.org This information is such information as Better Collective A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on March 5, 2021 at 7.3
TGS Share Repurchase5.3.2021 17:51:25 CET | Press release
Oslo, Norway (5 March 2021) – On period from 2 March 2021 to 4 March 2021, TGS-NOPEC Geophysical Company ASA (TGS) purchased 41,000 own shares on the Oslo Stock Exchange at an average price of NOK 141.2252 per share. Following the purchase, TGS holds 195,000 own shares, representing 0.166% of the total outstanding shares. The shares were purchased in connection with the share repurchase announced on 11 February 2021. Overview of transactionsDateAggregated daily volume (number of shares)Weighted average share price per day (NOK)Total daily transaction value (NOK)2-Mar-2120,000140.90672,818,1343-Mar-2120,000141.57002,831,4004-Mar-211,000140.7000140,700Previously disclosed buy-backs under the program (accumulated)79,000138.327910,927,901Accumulated under the buy-back program120,000139.317816,718,135The issuer's holding of own shares:Following the completion of the above transactions, TGS owns a total of 195,000 own shares, corresponding to 0.166% of TGS' share capital.Appendix:An overview
Bavarian Nordic to Host Full Year 2020 Results Conference Call5.3.2021 17:30:00 CET | Press release
COPENHAGEN, Denmark – March 5, 2021 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2020 annual report on Friday, March 12, 2021. The management of Bavarian Nordic will host a conference call at 2:00 pm CET (8:00 am EST) on the same day to present the full-year results followed by a Q&A session. A live and replay version of the call and relevant slides will be available at http://bit.ly/3rkKNed. To join the Q&A session dial one of the following numbers and state the participant code 5589045: Denmark: +45 32 72 80 42, UK: +44 (0) 844 571 8892, USA: +1 631-510-7495. About Bavarian Nordic Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection
Bavarian Nordic afholder telefonkonference i forbindelse med offentliggørelse af årsregnskabet for 20205.3.2021 17:30:00 CET | pressemeddelelse
KØBENHAVN, 5. marts 2021 – Bavarian Nordic A/S (OMX: BAVA) offentliggør årsregnskab for 2020 på fredag den 12. marts 2021. Samme dag afholder selskabets ledelse en telefonkonference kl. 14:00 dansk tid med henblik på at præsentere årsregnskabet og besvare eventuelle spørgsmål. Det er muligt at høre en live eller arkiveret webcast af telefonkonferencen samt downloade den tilhørende præsentation på http://bit.ly/3rkKNed. For at stille spørgsmål på telefonkonferencen, benyt venligst et af følgende telefonnumre og oplys deltagerkoden 5589045: Danmark: +45 32 72 80 42, UK: +44 (0) 844 571 8892, USA: +1 631-510-7495. Om Bavarian Nordic Bavarian Nordic er et fuldt integreret vaccineselskab, der er fokuseret på udvikling, produktion og kommercialisering af livsvigtige vacciner. Vi er globalt førende inden for koppevacciner, og er mangeårig leverandør til det amerikanske strategiske nationale beredskabslager af en ikke-replikerende koppevaccine, som er godkendt af de amerikanske sundhedsmyndigh
ASM INTERNATIONAL N.V. PUBLISHES ANNUAL REPORT 20205.3.2021 16:27:39 CET | Press release
Almere, The Netherlands March 5, 2021 ASM International N.V. (Euronext Amsterdam: ASM) today publishes its Annual Report 2020. For the first time, ASMI publishes the Annual Report in accordance with European Single Electronic Format (ESEF) reporting requirements with the format of the report being Extensible Hypertext Markup Language (xHTML). In line with the ESEF requirements, the primary consolidated financial statements have been labelled with XBRL tags. ASMI's Annual Report 2020 is available in ESEF reporting package, HTML file and as a PDF file on the company's website www.asm.com. ASMI will hold its Annual General Meeting of Shareholders (AGM) on May 17, 2021. The AGM agenda with all related documents will be available in due time. About ASM International ASM International NV, headquartered in Almere, the Netherlands, its subsidiaries and participations design and manufacture equipment and materials used to produce semiconductor devices. ASM International, its subsidiaries and pa
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS5.3.2021 16:20:00 CET | Press release
Anbudsförfarande kommuner och regioner, 2021-03-09BondsFixed rate notes issued in SEK by Municipalities or Regions with maturity in: 2024 The following issuers are accepted for delivery: Göteborgs Stad Helsingborgs Stad Jönköpings Kommun Malmö Stad Region Skåne Stockholms Stad Region Stockholm Delivery may not be made in Bonds purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after: 2021-02-26BidsBids are made to tel 08-696 69 70 and confirmed in writing by a filled-in Bid form by e-mail to EOL@riksbank.se Bid date2021-03-09Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 1000 +/- 1000 millionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 1 000 million. No bid may contain Bonds exceeding SEK 1000 million issued by Stockholms
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK TREASURY BILLS5.3.2021 16:20:00 CET | Press release
Bid procedure, 2021-03-08BillsSWEDISH T-BILL: SE0015504907. 2021-05-19 SWEDISH T-BILL: SE0014808747, 2021-09-15 Bid date2021-03-08Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SE0015504907: 500 mln SEK +/-250 mln SEK SE0014808747: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)SE0015504907: 500 mln SEK per bid SE0014808747: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-03-10Delivery of billsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-03-05 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and